Upcoming Events

SDASA Q4 Meeting and Seminar: Adaptive 2-in-1 design, expansion decision and extensions


Time: Oct 22, 2-3:30 pm PST. 
Registration Link: https://www.eventbrite.com/e/sdasa-q4-meeting-adaptive-2-in-1-design-expansion-decision-and-extensions-tickets-182039684597
Location: Virtual

"The 2-in-1 adaptive design [Chen et al. 2018] allows seamless expansion of an ongoing Phase 2 trial into a Phase 3 trial to expedite a drug development program. Under a mild assumption that is expected to generally hold in practice, the trial can be tested at the full alpha level with or without expansion. The endpoint used for expansion decision can be the same as or different from the primary endpoints, and there is no restriction on the expansion bar. Due to its flexibility and robustness, it has drawn immediate attention to academic researchers and industry practitioners. The design has been substantially extended in the literature and successfully implemented in multiple trials."

- Dr. Cong Chen is Executive Director of Early Oncology Development Statistics at Merck & Co., Inc.